Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Ariceum Therapeutics
Germany
- Berlin
- 19/04/2023
- Series A
- $27,393,000
Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Our lead targeted systemic radiopharmaceutical product, 177 Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours and childhood cancer, which currently has few treatment options and a poor prognosis.
Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen.
Headquartered in Berlin, Ariceum has operations in Germany and is active across Europe, North America and Australia.
- Industry Biotechnology Research
- Website https://ariceum-therapeutics.com/
- LinkedIn https://www.linkedin.com/company/ariceum-therapeutics/
Related People
Manfred RuedigerFounder
Germany -
Inning am Ammersee, Bavaria
Experienced Biotech Executive and Member of several non-executive Supervisory Boards with a deep track record of Science, M&A, IPO, licensing and restructuring companies in Europe and US. Broad expertise in Oncology, Immune Oncology, Inflammatory diseases, antibody and cell-based-approaches. Strong entrepreneurship professional with a PhD focused in Biochemistry and Molecular Biology from Eberhard-Karls-Universität Tübingen.
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)